An observational study in Hereditary Angioedema, sponsored by Intellia Therapeutics. Enrolling by invitation at 7 sites in 6 countries. Per ClinicalTrials.gov, last updated 2025-11-28.
Sponsored by Intellia Therapeutics · Observational
This is a follow-up study of subjects who received NTLA-2002 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.
171 studies on the registry are indexed under Angioedemas, Hereditary; 25 are open to participants now.
This study's planned enrollment of 100 is close to the median of 100 across 43 observational studies indexed under Angioedemas, Hereditary.
Browse Angioedemas, Hereditary studies →Intellia Therapeutics is the lead sponsor of 9 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participating sites in an Intellia-sponsored clinical study of NTLA-2002.
Exclusion Criteria:
None
Incidence of treatment-related Adverse Events (AEs); incidence of treatment-related Serious Adverse Events (SAEs); incidence of treatment-related Adverse Events of Special Interest (AESIs) defined per protocol
Time frame: up to 15 years
To evaluate the long-term efficacy of NTLA-2002 in previously treated subjects
Rate of Hereditary Angioedema (HAE) attacks overall and rate of HAE attacks requiring acute therapy. Total plasma kallikrein protein level.
Time frame: up to 15 years
Change from baseline in consumption of on-demand HAE medications for reported HAE attacks
Time frame: up to 15 years
Change from baseline in healthcare utilization for HAE attacks
Time frame: up to 15 years
Change from baseline in QoL parameters as measured by the MOXIE Angioedema-QoL instrument.
Time frame: up to 5 years
Change from baseline in QoL parameters as measured by the EQ-5D-5L instrument.
Time frame: up to 5 years
Change from baseline in QoL parameters as measured by the WPAI:GH instrument.
Time frame: up to 5 years
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intellia Therapeutics